Effect of Valprazolamide on the Content of Neuroactive Amino Acids in the Rat Brain

Malygin A. S.
Resident, Chair for Pharmacology and, Clinical Pharmacology¹

Popov N. S.
Assistant, Chair for Pharmacy¹

Demidova M. A.
MD, Professor, Head, Chair for Pharmacy¹

Kudrayshova M. N.
PhD (Biology), Associate Professor, Chair for Pharmacy¹

Bogomolova O. A.
Assistant, Chair for Pharmacy¹

1 - Tver State Medical University, Tver, Russia

Malygin Aleksandr; e-mail: dr.a.s.m@yandex.ru

None declared.

The study had no sponsorship.

In experiments on rats, the effect of valprazolamide, a new antiepileptic agent from the group of amide derivatives of valproic acid, on the brain content of neuroactive amino acids (GABA, glycine, glutamic and aspartic acids) was studied. Detection of amino acids was performed by gas chromatography-mass spectrometry. It was shown that a single intraperitoneal injection of valprazolamide (100 mg / kg) increases the level of GABA and the amide form of glutamic acid, reduces the levels of asparagine, glutamic and aspartic acids in the rat brain.

valproates, antiepileptics, γ-aminobutyric acid, glycine, aspartic acid, glutamic acid

10.29234/2308-9113-2019-7-1-99-108

1. Malygin A.S., Popov N.S., Demidova M.A. Eksperimental'noe issledovanie osobennostej metabolizma val'prazolamida [An experimental study of the metabolism of valprazolamide]. Verhnevolzhskij medicinskij zhurnal [Upper Volga Medical Journal] 2018; 17(4): 3-8. (In Russ.)

2. Mironov A.N. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [Manual for preclinical studies of pharmaceutical drugs]. Moscow: Grif i K., 2012. (In Russ.)

3. Pat. 2651572 Rossijskaya Federaciya, MPK A 61 K 31/433 N-(5-EHtil-1,3,4-tiadiazol-2-il)-2-propilpentanamid, obladayushchij protivoehpilepticheskoj i obezbolivayushchej aktivnostyami [Russian Federation Patent MPK A 61 K 31/433 H- (5-Ethyl-1,3,4-thiadiazol-2-yl) -2-propylpentanamide antiepileptic and analgesic activities]/ S.Ya. Skachilova, A.S.Malygin, N.S.Popov et al.; zayavitel' i patentoobladatel' OAO VNC BAV [Patent holder OAO VNC BAV]. – № 267288; decl. 13.03.2018; publ. 20.11.2018, Bull. № 32. (In Russ.)

4. Prikaz MZ RF ot 01.04.2016 № 199n «Pravila nadlezhashchej laboratornoj praktiki» [Ministry of Health Order of 01.04.2016 № 199n «On Good Laboratory Practice Rules»]. (In Russ.)

5. Frejdkova N.V., Pylaeva O.V., Muhin K.Yu. Val'parin HR v lechenii ehpilepsii (obzor literatury i opisanie klinicheskih sluchaev) [Valparin XP in the treatment of epilepsy (review of the literature and description of clinical cases)]. Russkij zhurnal detskoj nevrologii [Russian Journal of Pediatric Neurology] 2015; 10(3): 37-42. (In Russ.)

6. Shnajder N.A. Dmitrenko D.V. Hronicheskaya intoksikaciya val'proevoj kislotoj v ehpileptologii: diagnostika i lechenie [Chronic intoxication with valproic acid in epileptology: diagnosis and treatment]. Nevrologiya, nejropsihiatriya, psihosomatika [Neurology, neuropsychiatry, psychosomatics] 2016; 8(2): 94-99. (In Russ.)

7. Bertelsen F., Landau AM., Vase KH., Jacobsen J. et al. Acute in vivo effect of valproic acid on the GABAergic system in rat brain: A [11C]Ro15-4513 microPET study. Brain Res. 2018 Feb 1; 1680:110-114.

8. Göttlicher M., Minucci S., Zhu P., Krämer O. et al Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO Journal 2001; 20 (24): 6969-6978.

9. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2012; 16 (10): 695-714.

10. Piplani S, Verma PK, Kumar A. Neuroinformatics analyses reveal GABAt and SSADH as major proteins involved in anticonvulsant activity of valproic acid. Biomed Pharmacother. 2016; 81: 402-410.